user

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment

被引：0
|
作者：
Daungsupawong, Hinpetch [2 ]
Wiwanitkit, Viroj [1 ]
机构：
[1] Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci, Dept Res Analyt, Chennai, India
[2] Lak52 Phonhong, Viangchan, Laos
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2024年 / 20卷 / 01期
关键词：
HPV; vaccine; surveillance;
D O I：
10.1080/21645515.2024.2306032
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Post-marketing surveillance study to assess the safety and tolerability of an Inactivated Poliomyelitis Vaccine in Indian children
    Sharma, Hitt
    Dhere, Rajeev
    Parekh, Sameer
    Shewale, Sunil
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (11) : 2538 - 2542
  • [32] IMPACT OF 9-VALENT HUMAN PAPILLOMAVIRUS VACCINE ON VACCINATION OF ADOLESCENTS AND YOUNG ADULTS IN THE PACIFIC NORTHWEST
    Lindsay, B.
    Groom, H.
    Naleway, A.
    Guzman-Cottrill, J.
    Kurosky, S.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A85 - A85
  • [33] Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine
    Kukimoto, Iwao
    Matsumoto, Koji
    Takahashi, Fumiaki
    Iwata, Takashi
    Tanaka, Kohsei
    Yamaguchi-Naka, Mayuko
    Yamamoto, Kasumi
    Yahata, Hideaki
    Nakabayashi, Makoto
    Kato, Hisamori
    Tsuda, Naotake
    Onuki, Mamiko
    Yaegashi, Nobuo
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 251 (04): : 287 - 294
  • [34] Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
    Ding, Yuan
    Fu, Tingbo
    Zhou, Wenbin
    Zhang, Xiaobo
    Wang, Ruying
    Liao, Huiying
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [35] Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina
    Trogdon, Justin G.
    Shafer, Paul
    Lindsay, Brianna
    Coyne-Beasley, Tamera
    [J]. VACCINE, 2018, 36 (10) : 1304 - 1309
  • [36] Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
    Moreira, E. D.
    Giuliano, A. R.
    de Hoon, J.
    Iversen, O. -E.
    Joura, E. A.
    Restrepo, J.
    Van Damme, P.
    Vandermeulen, C.
    Ellison, M. C.
    Krick, A.
    Shields, C.
    Heiles, B.
    Luxembourg, A.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (02) : 396 - 403
  • [37] Post-marketing surveillance of the safety of levofloxacin in Japan
    Yamaguchi, Hiroki
    Kawai, Hitomi
    Matsumoto, Takuyuki
    Yokoyama, Hiroo
    Nakayasu, Toshio
    Komiya, Masahiro
    Shimada, Jingoro
    [J]. CHEMOTHERAPY, 2007, 53 (02) : 85 - 103
  • [38] Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV)
    Boey, Lise
    Curinckx, Ans
    Roelants, Mathieu
    Derdelinckx, Inge
    Van Wijngaerden, Eric
    De Munter, Paul
    Vos, Robin
    Kuypers, Dirk
    Van Cleemput, Johan
    Vandermeulen, Corinne
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (03) : E661 - E671
  • [39] Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study
    Lv, Huakun
    Wang, Shenyu
    Liang, Zhenzhen
    Yu, Wei
    Yan, Chuanfu
    Chen, Yingping
    Hu, Xiaosong
    Fu, Rong
    Zheng, Minghuan
    Group, Thomas
    Luxembourg, Alain
    Liao, Xueyan
    Chen, Zhiping
    [J]. VACCINE, 2022, 40 (23) : 3263 - 3271
  • [40] Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
    Garland, Suzanne M.
    Anagani, Manjula
    Bhatla, Neerja
    Chatterjee, Sukanta
    Lalwani, Sanjay
    Ross, Cecil
    Group, Thomas
    Lin, Jianxin
    Luxembourg, Alain
    Walia, Anuj
    Tu, Yingmei
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
12345